Aldesleukin Completed Phase 1 Trials for Renal Cancers / Melanoma Treatment

IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT00418496Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma
NCT01603212Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor
NCT00970996Cisplatin, Temozolomide, Abraxane, With Interleukin-2 and Interferon for Metastatic Melanoma